<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01962753</url>
  </required_header>
  <id_info>
    <org_study_id>PHRN10-VC/ ASAP</org_study_id>
    <nct_id>NCT01962753</nct_id>
  </id_info>
  <brief_title>Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)</brief_title>
  <acronym>ASAP</acronym>
  <official_title>Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to compare the brain amyloid load in fully, partially
      and non remitting depressed elderly patients at 8 weeks of antidepressant therapy, by using
      PET with [F18]AV45.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main aim of this study is to assess the brain amyloid load in treated depressed elderly
      subjects using PET with [F18]AV45. The investigators hypothesize that the brain amyloid load
      will be higher in non or partially remitting depressed subjects treated with antidepressants
      than in fully remitting ones. An additional two years follow-up will allow comparing the
      brain amyloid load at baseline between those who will have evolved towards MCI or MA and
      those who will not, including ApoE genotype, the cognitive performances at baseline, the
      hippocampus volume as assessed by MRI, the type and profile of mood disorder (number of past
      episodes, age at first episode, vascular risk factor profile, response profile to
      antidepressants), as covariates.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>standards uptakes values (SUVr)</measure>
    <time_frame>2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residual cognitive deficits</measure>
    <time_frame>2 years</time_frame>
    <description>The residual cognitive deficits (presence/absence) will be considered as a categorical variable.
The ApoE genotype will also be considered as categorical variables, as well as vascular risk factor profile, WMH at MRI. MADRS, NPI and IA scores as well as the hippocampus volume will be considered as continuous variables.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Elderly</condition>
  <condition>Major Depression</condition>
  <arm_group>
    <arm_group_label>18FAV45</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>18FAV45</intervention_name>
    <description>Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,</description>
    <arm_group_label>18FAV45</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Adult 60 years or older

          -  Native language : french

          -  Study period &gt; 7 years

          -  Major depression defined on the DSM-IV criteria assessed by MINI and HDRS score of 10
             or over

          -  Affiliation to the national health insurance system

          -  Signed informed consent

        Exclusion Criteria

          -  History of alcoholism or drug addiction

          -  MMSE less than or equal to 17

          -  Major depression with psychotic features

          -  Depressive episode resistant, patient who received two different antidepressants well
             conducted without significant therapeutic response

          -  Any current or past episode of mania, schizophrenia or any other psychotic disorder

          -  Any past history of stroke or Parkinson's disease

          -  Any current significant unstable illness

          -  Any past diagnosis of Alzheimer's disease

          -  Any current treatment by AcethylCholinesterae inhibitor, memantine or antidepressant
             therapy.

          -  Contraindications to MRI in patients with:

               1. Metallic foreign body eye.

               2. Any implanted electronic medical irremovably (pacemaker, neurostimulator,
                  cochlear implants ...)

               3. Metal heart valve,

               4. Vascular clips formerly located on cranial aneurysm.

          -  Contraindications to antidepressants

          -  History of progressive disease that can affect the central nervous system such as
             uncontrolled diabetes, blood pressure greater than or equal to 180/100; chronic lung
             disease with hypoxia, head trauma with loss of consciousness greater than or equal to
             15 minutes; brain surgery, encephalitis, recently treated cancer (&lt;1 year), altered
             cerebral metabolism including subjects with stroke sequelae extended. Patients with
             lacunar stroke without thalamic or striatal may be included.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent CAMUS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Tours</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent CAMUS</last_name>
    <phone>+33 247 47 91 30</phone>
    <email>vincent.camus@univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie GISSOT</last_name>
    <phone>+33 234 37 96 53</phone>
    <email>valerie.gissot@univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Besançon- Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre VANDEL</last_name>
      <email>pierre.vandel@univ-fcomte.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Caen</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia DOLLFUS</last_name>
      <email>dollfus-s@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean ROCHE</last_name>
      <email>Jean.ROCHE@CHRU-LILLE.FR</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe ROBERT</last_name>
      <email>robert.p@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sainte-Anne Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry GALLARDA</last_name>
      <email>T.GALLARDA@ch-sainte-anne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Le Rouvray Hospital</name>
      <address>
        <city>Sotteville lès Rouen</city>
        <zip>76300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie DESBORDES</last_name>
      <email>marie.desbordes@ch-lerouvray.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Strasbourg - HUS</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric BLANC</last_name>
      <email>frederic.blanc@chru-strasbourg.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Toulouse - Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe ARBUS</last_name>
      <email>arbus.c@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent CAMUS</last_name>
      <email>vincent.camus@univ-tours.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2013</study_first_submitted>
  <study_first_submitted_qc>October 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2013</study_first_posted>
  <last_update_submitted>February 13, 2015</last_update_submitted>
  <last_update_submitted_qc>February 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Affective symptoms as prodromal stage of Alzheimer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Plaque, Amyloid</mesh_term>
    <mesh_term>Affective Symptoms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

